MedTrace Logo

Marginal Zone Lymphoma Cohort in Korea

NCT02732236 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-04-18

No results posted yet for this study

Summary

Marginal zone lymphoma is a rare of subtype of Non-Hodgkin Lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observation study

Conditions

  • Lymphoma, B-Cell, Marginal Zone

Interventions

OTHER

Rituximab

Cohort observation study

Sponsors & Collaborators

  • Dong-A University Hospital

    lead OTHER

Principal Investigators

  • Sung Yong Oh · Consortium for improving survival of lymphoma office

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2020-02-29
Completion
2022-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02732236 on ClinicalTrials.gov